Scots schoolboy who suffered 800 seizures a month has his smile back after being prescribed cannabis oil
Gino Londra battles rare generic disorders 1p36 deletion syndrome and West Syndrome.
Updated
Gino s mum and dad are over the moon with Gino s progress (Image: Supplied)
Get the stories that matter to you sent straight to your inbox with our daily newsletter.Invalid EmailSomething went wrong, please try again later.
Subscribe
When you subscribe we will use the information you provide to send you these newsletters. Sometimes they’ll include recommendations for other related newsletters or services we offer. OurPrivacy Noticeexplains more about how we use your data, and your rights. You can unsubscribe at any time.
NICE guidance, for the first time in the UK, supports access to an advanced therapy for people with moderate as well as severe rheumatoid arthritis (RA) - aiming to avoid irreversible damage as early as possible
1
2
3
Mechelen, Belgium, 21 January 2021, 08:05 CET – Galapagos NV (Euronext & Nasdaq: GLPG) today welcomed the news that the
National Institute for Health and Care Excellence (NICE) has issued a final appraisal determination (FAD) recommending the use of the daily oral pill, JYSELECA
®
▼ (filgotinib) on the National Health Service (NHS) in England for the treatment of eligible adult patients with moderate to severe active rheumatoid arthritis (RA).
1 It is the first time in the UK that an advanced therapy has been recommended in people with moderate RA, offering thousands more the potential to achieve remission earlier - potentially slowing the irreversible damage and life-limiting symptoms RA can cause.
The Scottish Medicines Consortium has approved five new drugs for use by the NHS (Julien Behal/PA)
Sign up for our daily newsletter featuring the top stories from The Press and Journal.
Thank you for signing up to The Press and Journal newsletter.
Something went wrong - please try again later. Sign Up
A drug that can help patients with a rare and “devastating” type of lung cancer live longer, with a better quality of life, has been approved for use by the NHS.
The Scottish Medicines Consortium (SMC) gave the go ahead for doctors to use five new treatments – including the drug entrectinib, which is also known as Rozlytrek.
Date Time
MHRA Innovative Licensing and Access Pathway is open for business
The ambition of this new licensing and access pathway is to reduce the time to market for innovative medicines. The ILAP combines the MHRA’s globally recognised strengths of independence and high standards of quality, safety, and efficacy, with improved efficiency and flexibility, readying the MHRA for a new era in medicines approvals in the UK.
Central to realising this ambition is how the ILAP provides a single integrated platform for sustained collaborative working between the MHRA, partners and the medicine developer.
By harnessing expertise at the right time from the MHRA’s partners, the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC) and NHS England and NHS Improvement (NHSE&I), the ILAP allows for enhanced coordination and monitoring of important product development activities. Patients are also key partners and the patient voice will be integra
The MHRA Innovative Licensing and Access Pathway is open for business
The Medicines and Healthcare products Regulatory Agency (MHRA) today, 1 January 2021, formally starts the Innovative Licensing and Access Pathway (ILAP).
From:
1 January 2021
The ambition of this new licensing and access pathway is to reduce the time to market for innovative medicines. The
ILAP combines the
MHRA’s globally recognised strengths of independence and high standards of quality, safety, and efficacy, with improved efficiency and flexibility, readying the
MHRA for a new era in medicines approvals in the UK.
Central to realising this ambition is how the
ILAP provides a single integrated platform for sustained collaborative working between the